Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AIkido Pharma Inc. (AIKI : NSDQ)
 
 • Company Description   
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.31 Daily Weekly Monthly
20 Day Moving Average: 2,714,641 shares
Shares Outstanding: 89.29 (millions)
Market Capitalization: $27.33 (millions)
Beta: 1.55
52 Week High: $1.21
52 Week Low: $0.29
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.00% 0.74%
12 Week -22.53% -12.93%
Year To Date -47.85% -36.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE ROCKEFELLER PLAZA 11TH FLOOR
-
NEW YORK,NY 10020
USA
ph: 703-992-9325
fax: 703-992-9348
investorrelations@aikidopharma.com http://www.aikidopharma.com
 
 • General Corporate Information   
Officers
Anthony Hayes - Chief Executive Officer and Director
Robert J. Vander Zanden - Chairman of the Board
Tim S. Ledwick - Director
Paul LeMire - Director
Gregory James Blattner - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 008875106
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 89.29
Most Recent Split Date: 5.00 (0.24:1)
Beta: 1.55
Market Capitalization: $27.33 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.29
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -6.70
12/31/21 - -6.96
09/30/21 - -5.92
ROA
03/31/22 - -6.28
12/31/21 - -6.88
09/30/21 - -5.85
Current Ratio
03/31/22 - 110.82
12/31/21 - 85.66
09/30/21 - 54.07
Quick Ratio
03/31/22 - 110.82
12/31/21 - 85.66
09/30/21 - 54.07
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.06
12/31/21 - 1.13
09/30/21 - 1.15
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 18.80
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©